Abstract: 300/300 words Body: 3695/3700 words Identify which NMIBC patients benefit from a single immediate instillation. in non-muscle invasive bladder cancer, however it should not be given to patients at high risk of 34 recurrence due to its lack of efficacy in this subgroup. 
4
The instillation did not prolong either the time to progression or death from bladder cancer, but 21 resulted in an increase in the overall risk of death (HR = 1.26, 95% CI: 1.05 -1.51, p = 0.015, 5 22 year death rates 12.0% versus 11.2%), with the difference appearing in patients with an EORTC 23 recurrence score ≥ 5.
24

Conclusions
25
A single immediate instillation reduced the risk of recurrence, except in patients with a prior 26 recurrence rate > 1 recurrence/year or an EORTC recurrence score ≥ 5. It does not prolong 27 either time to progression or death from bladder cancer. The instillation may be associated 28 with an increase in the risk of death in patients at high risk of recurrence in whom the 29 instillation is not effective or recommended. 30 
31
Patient Summary
32
A single instillation of chemotherapy immediately after resection reduces the risk of recurrence 33 in non-muscle invasive bladder cancer, however it should not be given to patients at high risk of 34 recurrence due to its lack of efficacy in this subgroup. 
Introduction
38
In low and intermediate risk patients with non-muscle invasive bladder cancer (NMIBC), the 39 EAU NMIBC Guidelines Panel recommends a single immediate instillation of chemotherapy 40 after complete transurethral resection (TURB) [1] . This recommendation stems from a June 41 2004 literature based meta-analysis of a single immediate postoperative instillation of 42 chemotherapy. Analyzing data extracted from publications of 7 randomized controlled trials 43 (RCTs), the meta-analysis concluded that a single instillation significantly reduced the risk of 44 recurrence after TURB, odds ratio = 0.61, 95% CI: 0.49-0.75, p < 0.0001, number needed to treat 45 = 8.5 [2] . The AUA also supports use of an immediate postoperative instillation in patients with 46 small volume, low grade Ta tumors [3] . Despite these recommendations, an immediate 47 instillation of chemotherapy is not universally used in day to day clinical practice [4] [5] [6] [7] . 48 Several RCTs assessing the efficacy of an immediate instillation have been published since the 49 meta-analysis, some of which questioned its efficacy, especially in intermediate risk patients 50 [8]. One review called for it to be abandoned [9] . 51 One limitation of the meta-analysis was that it was not based on individual patient data so time 52 to recurrence, prognostic factor and subgroup analyses could not be carried out to identify 53 which patients benefit from the instillation. Likewise, two recent literature based meta-analyses 54 could not adequately answer this question [10 -11] . 55 To identify which patients benefit from an immediate instillation, a new systematic review and 56 meta-analysis using individual patient data has been undertaken. Figure 3 . This included the 2006 EORTC risk scores for recurrence and progression 114 [12] and the 2013 EAU risk group classification [1] . Subgroup analyses were carried out for 115 factors where the interaction was significant at 0.05. Exploratory non-randomized comparisons were carried out according to the chemotherapy, 117 delay between TURB and immediate instillation, and use of post-operative irrigation.
118
No studies or patients were excluded for quality reasons. reviewed by two reviewers. They identified 171 abstracts for which the full text was reviewed.
124
Abstracts of two potentially eligible but unpublished studies were identified [13, 14] . Attempts 125 to contact the authors of these studies were unsuccessful. One study was ineligible due to use 126 of fulguration instead of TURBT [15] . In another, a subgroup of 19 patients was potentially 127 eligible. Since there were no recurrences in these patients, they would have not contributed to 128 the treatment comparisons and were not included [16] . Three other potentially eligible was not possible to obtain individual patient data [30] [31] . In these two studies and the two 139 unpublished studies with abstracts [13] [14] Table 2 ). (Table 4 ).
222
The difference in survival is statistically significant in favor of no instillation with a relative The number of deaths due to bladder cancer is small and no interactions in Online Figure 9 246 were statistically significant, but similar trends were seen as for overall survival, with a 247 suggestion of a shorter disease specific survival on a single instillation in patients with 248 recurrence risk score > 5. Table 5 lists the cause of death by treatment group according to EORTC Recurrence Risk Score. was not a planned subgroup analysis and these differences could have occurred by chance. Non-randomized comparisons suggest the instillation is more effective when given within two 280 hours after TURB. Indirect comparisons could not detect any differences in efficacy between 281 mitomycin C and epirubicin.
282
Once the stage and grade are available, further treatment can be planned according to the risk 283 stratification [1] . 284 The benefit of an early instillation was most pronounced in low risk patients in whom no further 285 treatment before recurrence is recommended.
286
In intermediate risk patients, where the 5 year recurrence rate after a single instillation is nearly 287 40%, the results support EAU guideline recommendations that a single instillation alone is 288 insufficient and should be followed by further instillations [1] . A systematic review 289 demonstrated the best results for schedules where an early instillation preceded further 290 instillations of chemotherapy [34] . In high risk patients receiving BCG, the only study assessing a 291 single instillation was inconclusive [35] . 292 18 Recurrences in low risk patients are usually low stage, low grade [36, 37] . In this meta-analysis, 293 recurrences were mostly small, median size 3 mm. Theoretically, small recurrences can be 294 managed by office fulguration under local anesthesia without a significant burden to the 295 patient [9, 38, 39] . There are, however, no prospective randomized comparisons of this of recurrence may be at higher risk of (unrecognized) perforation, which could contribute to 311 their poor prognosis [41] . 312 Lamm et al [42] found that intravesical chemotherapy did not influence the long-term course of 313 the disease and raised concerns that repeated intravesical chemotherapy might be 314 carcinogenic, however the EORTC found no evidence of carcinogenicity in 3 studies with more 315 than 1200 patients [43, 44] . 316 This is the first meta-analysis to study this question which is based on individual patient data 317 with a relatively long follow up and identify patients who benefit or not from an immediate 
